Methods and materials for treating cancer
AssigneeMayo Foundation for Medical Education and Research
InventorsRichard G. Vile, Rosa M. Diaz Marcano, Timothy J. Kottke, Jason M. Tonne
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials involved in treating cancer. For example, methods and materials for using allogenic APCs (e.g., allogenic dendritic cells) designed to release a viral vector that can infect a T cell (e.g., an infectious retroviral vector or an infectious lentiviral vector) and drive expression of an antigen receptor (e.g., a CAR) within that T cell to produce dual specific CAR+ memory T cells and/or to treat cancer are provided.
Claims29
A method for treating a human having cancer, wherein said method comprises administering a population of human allogenic antigen presenting cells (APCs) to said human, wherein said allogenic APCs (i) comprise nucleic acid encoding a viral vector comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) targeting a cancer antigen of said cancer and (ii) release a population of said viral vectors within said human, wherein viral vectors of said population of released viral vectors infect a population of T cells within said human and are replication-defective within said infected T cells, wherein said infected T cells express said CAR, wherein at least some of said infected T cells expressing said CAR form dual specific effector T cells comprising said CAR, and wherein said effector T cells reduce the number of cancer cells within said human in the absence of any subsequence administration of human allogenic APCs to said human.
(canceled)
4-7. (canceled)
A method for treating a mammal having cancer, wherein said method comprises administering a population of allogenic APCs to said mammal, wherein said allogenic APCs (i) comprise nucleic acid encoding a viral vector comprising a nucleic acid sequence encoding a CAR targeting a cancer antigen of said cancer and (ii) release a population of said viral vectors within said mammal, wherein viral vectors of said population of released viral vectors infect a population of T cells within said mammal and are replication-defective within said infected T cells, wherein said infected T cells express said CAR, wherein at least some of said infected T cells expressing said CAR form dual specific effector T cells comprising said CAR, and wherein said effector T cells reduce the number of cancer cells within said mammal.
(canceled)
13-15. (canceled)
19-21. (canceled)
A method for generating memory T cells expressing a CAR within a human, wherein said method comprises administering a population of human allogenic APCs to said human, wherein said allogenic APCs (i) comprise nucleic acid encoding a viral vector comprising a nucleic acid sequence encoding said CAR and (ii) release a population of said viral vectors within said human, wherein viral vectors of said population of released viral vectors infect a population of T cells within said human and are replication-defective within said infected T cells, wherein said infected T cells express said CAR, and wherein at least some of said infected T cells expressing said CAR form a dual specific memory T cell within said human in the absence of a subsequent administration of human allogenic APCs to said human.
(canceled)
(canceled)
30-34. (canceled)
A method for generating memory T cells expressing a CAR within a mammal, wherein said method comprises administering a population of APCs to said mammal, wherein said APCs (i) comprise nucleic acid encoding a viral vector comprising a nucleic acid sequence encoding said CAR and (ii) release a population of said viral vectors within said mammal, wherein viral vectors of said population of released viral vectors infect a population of T cells within said mammal and are replication-defective within said infected T cells, wherein said infected T cells express said CAR, and wherein at least some of said infected T cells expressing said CAR form a dual specific memory T cell within said mammal.
40-48. (canceled)
Dependencies are inferred from the claim text.